Oxurion NV Expands GLP-1 and Peptide Research Services Amidst Market Growth

Oxurion NV Expands GLP-1 and Peptide Research Services Amidst Market Growth

Oxurion NV has announced an expansion of its clinical research services, specifically targeting the rapidly growing demand for GLP-1 and peptide therapeutics. This strategic move aligns with significant market trends and increasing clinical trial activity in these therapeutic areas. For BD teams and investors tracking outsourced metabolic disease research, the June 2 announcement signals a calculated bet on sustained demand that shows no signs of peaking.

Key Takeaways

• Oxurion NV launched a specialized service offering focused on GLP-1 therapies, peptide therapeutics, and biosimilar development on June 2, 2026.
• The expansion responds to a sevenfold increase in Phase I peptide clinical trials — from 18 in 2023 to 137 in 2025, per ClinicalTrials.gov data.
• The company is simultaneously exploring acquisition targets to broaden its capabilities beyond internal development.
• Oxurion's track record includes positive Phase 2 data for EYP-1901 in the DAVIO trial, providing relevant clinical development credibility.
• The EMA's increasing regulatory attention to biosimilar pathways adds complexity that specialized CROs are positioned to navigate.

Why Is Oxurion Expanding Into GLP-1 and Peptide Research?

Oxurion NV announced on June 2, 2026, that it is expanding its capabilities to address the growing demand for GLP-1 and peptide clinical research services. The company launched a dedicated service offering spanning GLP-1 therapies, peptide therapeutics, and biosimilar development. This is not a diversification play — it is a direct response to quantifiable demand. Analysis of ClinicalTrials.gov data shows Phase I peptide clinical trials surged from 18 in 2023 to 137 in 2025, a more than sevenfold increase in just two years. Generalist CROs are struggling to keep pace with the specialized trial design, bioanalytical, and regulatory expertise these programs require.

Oxurion's leadership has signaled that the expansion is part of a broader growth strategy. The company's annual report noted it is "actively exploring potential targets for acquisition" to broaden its service portfolio. That dual approach — building specialized internal capabilities while scouting external assets — suggests management intends to scale quickly rather than grow organically alone.

What Is Driving the GLP-1 and Peptide Boom?

The pharmaceutical market is experiencing a structural shift in metabolic disease therapeutics. GLP-1 receptor agonists have moved from niche diabetes treatments to blockbuster obesity and cardiometabolic drugs, attracting billions in R&D investment. The emergence of oral GLP-1s has accelerated this trend further. Orforglipron (Foundayo) recently secured approval, marking a pivotal moment: the transition from injectable peptides to oral small molecules that mimic GLP-1 signaling. Analysts have dubbed these "gliprons" and compared their market potential to the Ozempic phenomenon.

Allurion, a company with a different operational model, has also pivoted toward this space, announcing a strategic focus on low-dose GLP-1 combination therapy and muscle mass maintenance for the US market. The fact that companies across different segments — device-based weight management, oral therapeutics, and contract research — are all converging on GLP-1 validates the durability of this demand cycle.

For CROs, the opportunity extends beyond innovator drugs. As first-generation GLP-1 patents approach expiration, biosimilar development is becoming a meaningful revenue stream. The EMA has been refining its regulatory framework for biosimilar peptides, creating a pathway that demands specialized analytical and clinical expertise. Oxurion's decision to include biosimilar development in its service launch positions it at the intersection of two growth curves simultaneously.

How Does This Impact BD Teams and Investors?

For business development teams at biotech firms developing GLP-1 or peptide candidates, Oxurion's expanded capabilities present a concrete partnership opportunity. Specialized CROs in this space can compress timelines by bringing pre-optimized bioanalytical methods, experienced peptide formulation teams, and regulatory relationships that generalist providers lack. In a market where speed to Phase II readouts can determine licensing valuations, that operational advantage matters.

Investors should view the expansion through two lenses. First, it aligns Oxurion NV with a high-growth, high-margin service segment. The GLP-1 and peptide CRO market is expanding faster than the broader clinical research outsourcing market, and early movers with domain expertise tend to command premium pricing as the market matures. Second, Oxurion's concurrent exploration of acquisition targets suggests management is building toward a more comprehensive platform — if executed well, this could meaningfully expand the company's addressable market.

Oxurion's clinical development track record provides additional context. The company reported positive safety and efficacy data for EYP-1901 in its Phase 2 DAVIO clinical trial, and per its SEC filings, it continues to evaluate EYP-1901 in Phase 2 development. That internal pipeline activity gives the company firsthand understanding of the operational challenges its CRO clients face — a credibility advantage when competing for contracts.

What Should Stakeholders Watch Next?

The critical execution milestones are straightforward. BD teams should monitor whether Oxurion secures its first GLP-1 or peptide service contracts under the new offering, and whether those contracts come from established pharma or emerging biotech clients. The client mix will signal market positioning. Investors should track revenue contribution from the new services over the next four quarters — contracted backlog and revenue recognition will matter more than press releases.

On the acquisition front, any announced targets will reveal whether Oxurion is pursuing capability gaps (bioanalytical labs, regulatory consulting) or geographic expansion. Given the company's stated strategy, a bolt-on acquisition within 12 months of the service launch would be consistent with management's playbook.

Regulatory developments also bear watching. The EMA's evolving guidance on peptide biosimilar pathways could either accelerate or complicate the demand environment. Oxurion's ability to translate regulatory complexity into a competitive moat for its clients will be a key differentiator.

Frequently Asked Questions

Related coverage

• OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress
• ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
• Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress